Chief executive, Forte Biosciences
Appears in 1 story
Stepped down as director when the merger closed
argenx, a Belgian immunology company, closed its $2.2 billion takeover of Forte Biosciences on August 27, 2026. Forte is now a wholly owned subsidiary and its shares have been delisted from Nasdaq.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
